VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

Partnership Combines VERAXA’s Proprietary ADC Technology with OmniAb’s Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors.